Vitalant Specialty Laboratories & Therapeutics

Transfusion Medicine Updates

Below is a complete list of all Transfusion Medicine Updates published from February 1992 to the present that are relevant to the Coagulation Laboratory.

2011
Issue #1 Dabigatran, a New Oral Anticoagulant & Its Role in Clinical Practice Irina Chibisov, M.D.
Andrea Cortese Hassett, Ph.D.
2010
No revelant issues.
2009
Issue #3 Clopidogrel (Plavix®) Monitoring Andrea Cortese Hassett, Ph. D.
2008
No relevant issues
2007
Issue #6 Strategies for Reversal of Anticoagulants, Part 2: The Newer Anticoagulant Agents Irina Chibisov, M.D.
Issue #5 Strategies for Reversal of Anticoagulants, Part 1: Warfarin, Unfractionated Heparin and Low Molecular Weight Heparins Irina Chibisov, M.D.
Issue #3 Von Willebrand Disease Minh-Ha Tran, D.O.
Issue #2 Off-label use of Recombinant Factor VIIa (rFVIIa) Suzanne Bakdash, M.D., M.P.H.
Franklin A. Bontempo, M.D.
2006
Issue #4 Review of International Consensus Statement On An Update of the Classification Criteria for Definite Antiphospholipid Syndrome Zella R. Zeigler, M.D.
2005
Issue #4 Aspirin Resistance Zella Zeigler, M.D.
2004
Issue #3 Quantitative D-dimer: Ruling out Venous Thrombosis Andrea Cortese Hassett, Ph. D.
2003
Issue #6 Hyperhomocysteinemia Andrea Cortese Hassett Ph.D.
2002
Issue #5 Platelet Function Testing Andrea Coretese Hassett, Ph.D.
Issue #4 New Therapy For Cold Autoimmune Hemolytic Anemia Ram Kakaiya, M.D.
Issue #3 DIC, Sepsis, Inflammation and Activated Protein C (APC) Kimberly Schlesinger, M.D.
Margaret Ragni, M.D.
Issue #2 New Anticoagulants in Clinical Practice Joseph E. Kiss, M.D.
Issue #1 Laboratory Evaluation of Thrombophilia in Recurrent Pregnancy Loss Kathleen E. Puca, M.D.
2001
May The Lupus Anticoagulant - An Update Franklin A. Bontempo, M.D.
January Activated Protein C Resistance Andrea Cortese-Hassett, Ph.D.
Franklin A. Bontempo, M.D.
2000
July Closure Time Platelet Function Screening Andrea Cortese Hassett, Ph.D.
February D-dimer Testing and Acute Venous Thromboembolism Andrea Cortese-Hassett, Ph.D.
January Antiplatelet Agents Franklin A. Bontempo, M.D.
1999
November / December RECOMBINANT FACTOR VIIa: A New Product for Factor VIII and IX Inhibitors Margaret V. Ragni, M.D.
September Platelet Transfusion Therapy Darrell J. Triulzi, M.D.
May Nucleic Acid Amplification Testing Arell Shapiro, M.D.
March Disseminated Intravascular Coagulation Agnes Aysola, M.D.
Ileana Lopez-Plaza, M.D.
February Laboratory Monitoring of Anticoagulant Therapy Andrea Cortese Hassett, Ph.D.
1998
August / September Acquired Inhibitors to Factor VIII Margaret Ragni, M.D.
June The Prothrombin Variant Franklin A. Bontempo, M.D.
February / March Optimizing the INR to Improve Oral Anticoagulant Monitoring Andrea Cortese Hassett, Ph.D.
January New Anticoagulants Franklin A. Bontempo, M.D.
1997
August Hereditary Hemachromatosis Andrea Coretese Hassett, Ph.D.
Joseph E. Kiss, M.D.
January Heparin-Induced Thrombocytopenia Franklin A. Bontempo, M.D.
1996
June Low Molecular Weight Heparin Franklin A. Bontempo, M.D.
Andrea Cortese Hassett, Ph.D.
February Heparin Monitoring Andrea Cortese-Hassett, Ph.D.
1995
August The Factor V Leiden Mutation Franklin A. Bontempo, M.D.
Andrea Cortese Hassett, Ph.D.
June The INR (International Normalized Ratio) FOR Monitoring Oral Anticoagulant Therapy Andrea Cortese-Hassett, Ph.D.
Frank A. Bontempo, M.D.
1994
November The Activated Protein C Resistance Test Franklin A. Bontempo, M.D.
Andrea Cortese Hassett, Ph.D.
October von Willebrand Disease Margaret V. Ragni, M.D., M.P.H.
April Use and Misuse of the Bleeding Time Franklin A. Bontempo, M.D.
1992
December The Lupus Anticoagulant Franklin A. Bontempo, M.D.
November Newer Approaches to Treatment of Hemophilia and von Willebrand's Disease Margaret V. Ragni, M.D.
Effective March 1, 2020, the maximum turn around times for our molecular assays will be updated to align with current laboratory practices.